信立泰(002294.SZ):阿利沙坦酯納入醫保目錄
格隆匯11月28日丨信立泰(002294.SZ)公佈,根據國家醫保局、人力資源社會保障部發布的《關於將2019年談判藥品納入〈國家基本醫療保險、工傷保險和生育保險藥品目錄〉乙類範圍的通知》(醫保發〔2019〕65號),公司的創新藥阿利沙坦酯(規格分別為80mg/片及240mg/片),通過談判續約,納入《國家基本醫療保險、工傷保險和生育保險藥品目錄》乙類範圍。
藥品名稱為阿利沙坦酯醫保,支付標準為2.62元(80mg/片),6.08元(240mg/片);協議有效期為2020年1月1日至2021年12月31日。在協議期內,產品按照乙類藥品有關規定支付,各地不得將談判藥品調出目錄,也不得調整限定支付範圍。
信立坦(阿利沙坦酯)用於輕、中度原發性高血壓的治療,是唯一由國內自主研發、擁有自主知識產權(1.1類新藥)的血管緊張素II受體拮抗劑類降壓藥物。信立坦降壓起效更快更強;降壓平穩;不依賴肝臟細胞色素P450酶,聯合用藥更安全;長期使用降低血尿酸,具有靶器官保護作用,安全性更高;並獲得2017年版《高血壓合理用藥指南》推薦。
信立坦於2017年7月通過談判納入醫保目錄,本次談判成功續約,體現了國家對具有臨牀價值創新產品的支持,有利於信立坦的市場推廣和銷售;為實現創新產品在公司營業收入、利潤佔比提升的戰略目標奠定堅實基礎;對公司朝創新藥方向發展產生積極的影響;同時,公司正不斷完善創新產品佈局,加快創新驅動發展步伐,以實現長遠、健康發展。
醫保目錄將於2020年1月1日起正式實施,對公司本報告期業績不會造成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.